S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.10
+62.50
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PEPG · PepGen Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$2.73
-0.15
(-5.04%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.73
$2.72
$2.98
52-WEEK RANGE
$2.73
$1.31
$7.80
What's happening
- PEPG is down 5.04% today, trading at $2.73. — Live quote
- Volume today (138,288) is well below its 3-month average of 936,050. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.26 actual vs. $-0.30 estimated (+12.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 5
Hold 1
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PEPG
-55.91%
vs S&P 500
-68.69%
1-YEAR RETURN
PEPG
-42.02%
vs S&P 500
-56.58%
6-MONTH RETURN
PEPG
+71.86%
3-MONTH RETURN
PEPG
+35.38%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.26
Est. $-0.30
BEAT +12.1%
2026-04-26 (Q1 2026)
$-0.26
Est. $-0.32
BEAT +18.3%
2026-01-26 (Q4 2025)
$-0.27
Est. $-0.38
BEAT +29.3%
2025-10-26 (Q3 2025)
$-0.52
Est. $-0.58
BEAT +9.8%
Valuation Measures & Ratios
Enterprise Value4$176.0M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book71.04
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-51.01%
Return on Assets (ROA9)-43.49%
Avg Volume (3M)936,050
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $123.3M | $119.2M | $159.8M | $36.8M | $46.1M |
| P/E | -1.61 | -1.34 | -1.72 | -0.36 | -0.47 |
| Price/Book | 1.03 | 0.89 | 0.98 | 0.52 | 0.50 |
| EV/EBITDA | -1.27 | -0.84 | -0.18 | — | — |
| ROE | -64.16% | -66.49% | -56.82% | -144.76% | -106.68% |
| ROA | -54.24% | -56.99% | -48.77% | -100.75% | -76.88% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,225,473
Change from Prior Settlement+9.15%
% of Float—
Days to Cover (Short Ratio)4.77
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -42.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PEPG
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.9M | -$18.9M | -$18.7M | -$23.9M | -$31.3M | -$23.2M | -$30.4M | -$19.8M |
| Net income | -$17.8M | -$17.8M | -$18.0M | -$23.1M | -$30.2M | -$21.4M | -$28.3M | -$18.0M |
| EPS (diluted) | $-0.26 | $-0.26 | $-0.52 | $-0.70 | $-0.92 | $-0.66 | $-0.87 | $-0.63 |
| EPS (basic) | $-0.26 | $-0.26 | $-0.52 | $-0.70 | $-0.92 | $-0.66 | $-0.87 | $-0.63 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $141.4M | $156.3M | $173.9M | $190.1M | $102.2M | $127.4M | $150.9M | $170.2M |
| Total liabilities | $21.9M | $22.3M | $26.5M | $26.9M | $31.1M | $35.6M | $32.3M | $32.8M |
| Stockholders' equity | $119.5M | $134.0M | $147.4M | $163.1M | $71.2M | $91.8M | $118.6M | $137.5M |
| Total current assets | $120.3M | $134.3M | $151.0M | $166.2M | $77.5M | $101.0M | $123.8M | $142.4M |
| Total current liabilities | $9.0M | $9.0M | $12.6M | $12.6M | $16.4M | $20.4M | $16.7M | $16.8M |
| Cash & equivalents | $22.8M | $42.1M | $60.5M | $142.8M | $35.1M | $43.6M | $49.4M | $42.3M |
| Marketable securities (current) | $94.5M | $90.2M | $87.9M | $20.9M | $39.6M | $54.1M | $70.8M | $96.6M |
| Property, plant & equipment | $1.3M | $1.6M | $1.9M | $2.2M | $2.5M | $3.5M | $3.7M | $3.9M |
| Other non-current assets | $265.0K | $389.0K | $372.0K | $372.0K | $426.0K | $426.0K | $426.0K | $426.0K |
| Accounts payable | $1.1M | $622.0K | $822.0K | $766.0K | $856.0K | $2.7M | $1.8M | $5.9M |
| Accrued liabilities | $4.7M | $5.1M | $8.6M | $8.7M | $12.4M | $14.6M | $11.8M | $7.8M |
| Common stock & paid-in capital | $7.0K | $7.0K | $7.0K | $7.0K | $3.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$396.7M | -$378.9M | -$361.1M | -$342.8M | -$324.8M | -$301.7M | -$271.5M | -$249.2M |
| Accumulated other comprehensive income (loss) | -$117.0K | -$59.0K | $11.0K | -$25.0K | -$43.0K | -$22.0K | $23.0K | $91.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.8M | -$18.4M | -$15.8M | -$19.3M | -$23.6M | -$22.9M | -$19.5M | -$24.0M |
| Investing cash flow | -$3.5M | -$1.5M | -$66.2M | $18.9M | $15.0M | $17.1M | $26.5M | -$133.0K |
| Financing cash flow | -$65.0K | $1.5M | -$171.0K | $108.1M | $98.0K | $0 | $128.0K | $327.0K |
| Free cash flow | -$15.8M | -$18.4M | -$15.8M | -$19.4M | -$23.6M | -$23.1M | -$19.7M | -$24.2M |
| Capital expenditures | $30.0K | $0 | -$1.0K | $97.0K | $43.0K | $125.0K | $228.0K | $185.0K |
| Depreciation & amortization | $300.0K | $300.0K | $1.0M | $300.0K | $300.0K | $400.0K | $1.1M | $400.0K |
| Share-based compensation | $3.3M | $2.9M | $2.4M | $2.4M | $2.4M | $3.4M | $3.3M | $3.2M |
| Purchases of investments | $53.5M | $28.5M | $87.2M | $0 | $0 | $6.7M | $21.3M | $29.9M |
| Sales/maturities of investments | $50.0M | $27.0M | $21.0M | $19.0M | $15.0M | $24.0M | $48.0M | $30.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$93.6M | -$97.7M | -$84.8M | -$68.3M | -$27.1M |
| Net income | -$89.7M | -$90.0M | -$78.6M | -$69.1M | -$27.3M |
| EPS (diluted) | $-2.12 | $-2.85 | $-3.30 | $-4.42 | $-30.27 |
| EPS (basic) | $-2.12 | $-2.85 | $-3.30 | $-4.42 | $-30.27 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $173.9M | $150.9M | $143.1M | $217.4M | $143.6M |
| Total liabilities | $26.5M | $32.3M | $34.6M | $37.8M | $10.5M |
| Stockholders' equity | $147.4M | $118.6M | $108.4M | $179.6M | -$32.1M |
| Total current assets | $151.0M | $123.8M | $112.7M | $186.1M | $140.0M |
| Total current liabilities | $12.6M | $16.7M | $17.5M | $18.8M | $10.3M |
| Cash & equivalents | $60.5M | $49.4M | $80.8M | $181.8M | $132.9M |
| Marketable securities (current) | $87.9M | $70.8M | $29.6M | $0 | — |
| Property, plant & equipment | $1.9M | $3.7M | $4.8M | $3.3M | $636.0K |
| Other non-current assets | $372.0K | $426.0K | $442.0K | $1.5M | $3.0M |
| Accounts payable | $822.0K | $1.8M | $1.0M | $1.4M | $3.2M |
| Accrued liabilities | $8.6M | $11.8M | $13.5M | $11.9M | $7.1M |
| Common stock & paid-in capital | $7.0K | $3.0K | $2.0K | $2.0K | — |
| Retained earnings | -$361.1M | -$271.5M | -$181.5M | -$102.9M | -$33.8M |
| Accumulated other comprehensive income (loss) | $11.0K | $23.0K | $34.0K | -$81.0K | $17.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$81.6M | -$82.4M | -$69.0M | -$59.3M | -$22.6M |
| Investing cash flow | -$15.2M | -$37.7M | -$32.0M | -$3.8M | -$500.0K |
| Financing cash flow | $108.0M | $88.7M | -$189.0K | $112.2M | $147.7M |
| Free cash flow | -$81.9M | -$82.9M | -$71.6M | -$63.0M | -$23.1M |
| Capital expenditures | $264.0K | $497.0K | $2.6M | $3.8M | $500.0K |
| Depreciation & amortization | $1.4M | $1.5M | $1.2M | $500.0K | $200.0K |
| Share-based compensation | $10.6M | $11.5M | $7.0M | $4.8M | $1.5M |
| Purchases of investments | $94.0M | $145.2M | $29.4M | — | — |
| Sales/maturities of investments | $79.0M | $108.0M | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PEPG as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-26 to 2026-05-21
Recent transactions
- Insiders have net sold 1,233 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Kasraian Kasra (Chief Technical Officer) — Open market sale of 1,233 shares on 2026-05-21.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)1,233 sh(1 txns)
Net Shares-1,233
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kasraian Kasra | Chief Technical Officer | Open market sale | 2026-05-21 | 1,233 |
| STRECK PAUL | EVP, Head of R&D | Open market sale | 2026-03-04 | 1,832 |
| Donnelly Noel | Chief Financial Officer | Open market sale | 2026-03-04 | 2,032 |
| McArthur James G | President and CEO | Open market sale | 2026-03-04 | 5,144 |
| Vittiglio Joseph | Chief Business & Legal Officer | Grant / award | 2026-03-01 | 30,717 |
| Oxford Science Enterprises plc | Former 10% Owner | Open market purchase | 2025-09-30 | 200,000 |
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 2025-09-26 | 9,375,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-21 | Kasraian Kasra | Chief Technical Officer | Open market sale | 1,233 | $1.41 |
| 2026-03-04 | STRECK PAUL | EVP, Head of R&D | Open market sale | 1,832 | $6.23 |
| 2026-03-04 | STRECK PAUL | EVP, Head of R&D | Open market sale | 47 | $6.29 |
| 2026-03-04 | Donnelly Noel | Chief Financial Officer | Open market sale | 2,032 | $6.23 |
| 2026-03-04 | Donnelly Noel | Chief Financial Officer | Open market sale | 52 | $6.33 |
| 2026-03-04 | McArthur James G | President and CEO | Open market sale | 5,144 | $6.23 |
| 2026-03-04 | McArthur James G | President and CEO | Open market sale | 131 | $6.33 |
| 2026-03-01 | Vittiglio Joseph | Chief Business & Legal Officer | Grant / award | 30,717 | $0.00 |
| 2026-03-01 | Kasraian Kasra | Chief Technical Officer | Grant / award | 34,557 | $0.00 |
| 2026-03-01 | STRECK PAUL | EVP, Head of R&D | Grant / award | 50,300 | $0.00 |
| 2026-03-01 | Donnelly Noel | Chief Financial Officer | Grant / award | 76,793 | $0.00 |
| 2026-03-01 | McArthur James G | President and CEO | Grant / award | 187,688 | $0.00 |
| 2025-12-08 | Vittiglio Joseph | Chief Business & Legal Officer | Grant / award | 35,000 | $0.00 |
| 2025-09-30 | Oxford Science Enterprises plc | Former 10% Owner | Open market purchase | 200,000 | $3.20 |
| 2025-09-26 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 9,375,000 | $3.20 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:10 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-05-26 | 4 | 2026-05-21 | View on SEC.gov → |
Recent news
Headlines about PEPG (PepGen Inc.). Links open the publisher — we don’t host full articles.
-
PepGen GAAP EPS of -$0.26
Seeking Alpha · 2026-08-06 -
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Yahoo Finance · 2026-08-06 -
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
Yahoo Finance · 2026-08-06 -
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Yahoo Finance · 2026-05-20 -
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?
Yahoo Finance · 2026-05-18 -
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
Yahoo Finance · 2026-05-13 -
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
Yahoo Finance · 2026-05-12 -
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway
Yahoo Finance · 2026-04-01
No headlines in this category right now — try “All”.